| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Artivion, Inc.$24.09
-0.02 (-0.08%)
F 17Pipeline Score MedTech · Commercial
Market Cap
991.26 M
EPS
0.25
P/E Ratio
85.05 $
Value Trade
13.10 M
SEC Financials
Q1 2026Dilution Risk
Revenue
116.34 M
R&D Expenses
8.84 M
Operating CF
1.15 M
Total Assets
883.16 M
Total Liabilities
432.69 M
Equity
450.47 M
D/E Ratio
12,345
-2.01 %
Week
-39.44 %
1 Month
-40.64 %
3 Month
-48.88 %
6 Month
-28.45 %
5 Year
461.5 %
All Time
Cash Data
Cash Position
55.76 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
333.27 K
52 Week Range
19.16 - 48.25
% held by Insiders
5.1 %
% held by Institutions
91.38 %
Enterprise Value
1.19 B
Total Shares
48.47 M
Short %
4.79 %
Float Shares
45.46 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artivion, Inc.
3Total events
1Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 17%
Micro Cap (rank 758 of 912)
Percentile RankArtivion, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NEXUS Aortic Arch System | chronic dissection, aneurysm, or other arch disease | — | 2026-02-02 | survival rate: 94%; freedom from disabling stroke: 91%; free from reintervention due to endoleaks: 97%; no occurance of renal failure: true; one occurance of paraplegia: true Read More | Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting Read More | |
NEXUS Aortic Arch System | chronic dissection, aneurysm, or other arch disease | — | 2026-02-02 | survival rate: 94%; freedom from disabling stroke: 91%; free from reintervention due to endoleaks: 97%; no occurance of renal failure: true; one occurance of paraplegia: true Read More | Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting Read More | |
NEXUS Aortic Arch System | chronic dissection, aneurysm, or other arch disease | — | 2026-02-02 | survival rate: 94%; freedom from disabling stroke: 91%; free from reintervention due to endoleaks: 97%; no occurance of renal failure: true; one occurance of paraplegia: true Read More | Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AORT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AORT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AORT▼ -5.2%on this news
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion, Inc. has received FDA approval for its AMDS Hybrid Prosthesis, aimed at treating acute DeBakey Type I aortic dissections. This approval allows hospitals to implant the device without the need for institutional review board approval, streamlining the process. Clinical data indicates a significant reduction in mortality and complications associated with the device, positioning Artivion for a substantial market opportunity.
Read more →AORTArtivion to Participate in the 2026 Truist Securities MedTech Conference
Artivion, Inc. will participate in the 2026 Truist Securities MedTech Conference on June 16, 2026. The event will feature a fireside chat at 1:00 p.m. ET, accessible via a live webcast on the company's website. Artivion specializes in medical devices for aortic diseases and has a diverse product range sold in over 100 countries.
Read more →AORTthan 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com. About Endospan Ltd. Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the
Artivion, Inc. has successfully completed the acquisition of Endospan Ltd., enhancing its portfolio in the aortic arch market. The acquisition includes the NEXUS Aortic Arch System, which has received FDA approval for its premarket application. Artivion plans to utilize a $150 million loan for the acquisition costs, positioning itself as the sole company with a full suite of aortic arch solutions globally. This move is expected to strengthen Artivion's leadership in addressing aortic disease treatments.
Read more →AORTArtivion Completes Acquisition of Endospan Ltd.
Artivion, Inc. has successfully acquired Endospan Ltd., enhancing its capabilities in aortic disease treatment. The acquisition includes the NEXUS Aortic Arch System, which received FDA approval in April 2026. This move positions Artivion as a leader in the aortic arch market, providing a comprehensive portfolio of solutions. The deal was funded by a $150 million loan, with additional performance-based considerations.
Read more →AORTEndospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Artivion, Inc. has completed the acquisition of Endospan following the FDA's approval of the NEXUS® Aortic Arch System. This acquisition is anticipated to strengthen Artivion's portfolio in the aortic arch market. The FDA's PMA approval marks a significant milestone for the NEXUS® system, enhancing its market potential.
Read more →AORTArtivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter ...
Artivion, Inc. reported strong financial results for the first quarter of 2026, showcasing a revenue increase to $116.3 million and significant growth in adjusted EBITDA. The company announced the exercise of its option to acquire Endospan, enhancing its aortic arch solutions portfolio following FDA approval for the NEXUS Aortic Arch System. Despite a slight decrease in full-year revenue guidance, Artivion maintains confidence in its long-term strategies and growth potential in the aortic disease market.
Read more →AORTArtivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone 332-895-3222 Chief Operating Officer investors artivion.com Chief Financial Officer Phone 770-419-
Artivion, Inc. announced its first quarter 2026 financial results, reporting an 18% increase in revenue and a net income of $1.4 million. The company received U.S. FDA PMA approval for the NEXUS Aortic Arch System and exercised an option to acquire Endospan for $135 million. Despite a strong start to the year, Artivion revised its 2026 revenue outlook downward, anticipating total revenues of $480 to $496 million. Additionally, the company expects negligible revenue from NEXUS sales until its launch in January 2027.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Artivion, Inc. announced that it will release its first quarter 2026 financial results on May 7, 2026, after market close. A teleconference will follow at 4:30 p.m. ET, hosted by CEO Pat Mackin. Investors can access the live webcast and a replay on the company's website, along with the earnings press release.
Read more →AORT▲ +5.3%on this news
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
Artivion, Inc. has received FDA approval for the NEXUS Aortic Arch System, developed by Endospan. This system offers a minimally invasive treatment option for aortic arch disease, including chronic aortic dissections. The approval is based on promising trial data showing high survival rates and low complications. Artivion is now evaluating its option to acquire Endospan within 90 days.
Read more →AORTArtivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Artivion, Inc. will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026. The company's presentation will focus on its advancements in cardiac and vascular surgery, particularly related to aortic diseases. A live webcast will be available on their website, with an archived version accessible for 90 days.
Read more →AORT▼ -10%on this news
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
Artivion, Inc. reported strong financial results for Q4 and the full year 2025, with a 13% revenue growth and a 26% increase in adjusted EBITDA. The company highlighted significant growth in stent grafts and On-X products. Positive clinical trial data was presented at a major conference, reinforcing confidence in future growth. For 2026, Artivion anticipates revenue growth between 10% to 14%.
Read more →AORTArtivion Gilmartin Group LLC Lance A. Berry Brian Johnston Laine Morgan Executive Vice President, Phone 332-895-3222 Chief Operating Officer investors artivion.com Chief Financial Officer P
Artivion, Inc. (NYSE: AORT) reported strong financial results for the fourth quarter and full year of 2025, showcasing revenue and income growth compared to 2024. The company achieved GAAP revenue of $441.3 million and adjusted revenues of $443.6 million, reflecting a year-over-year increase. Additionally, positive clinical data were shared from the NEXUS TRIOMPHE IDE trial, highlighting favorable patient outcomes. For 2026, Artivion forecasts further revenue growth and adjusted EBITDA increases, indicating continued confidence in its performance.
Read more →AORTArtivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion presented promising clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials at the 62nd Society of Thoracic Surgeons Annual Meeting. The NEXUS TRIOMPHE trial showed a 94% survival rate and 91% freedom from disabling stroke at one year. The AMDS PERSEVERE trial highlighted ongoing clinical benefits and positive aortic remodeling after two years.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
Artivion, Inc. has announced that it will release its fourth quarter 2025 financial results on February 12, 2026, after market close. A teleconference and live webcast will follow at 4:30 p.m. ET, hosted by CEO Pat Mackin. Investors can access the earnings press release and participate in the Q&A session.
Read more →AORT▼ -5.5%on this news
Artivion Reports Third Quarter 2025 Financial Results
Artivion, Inc. reported strong financial results for Q3 2025, with total revenues reaching $113.4 million, an 18% increase year-over-year. The company achieved significant growth in stent grafts and On-X products, alongside a successful patient enrollment in the ARTIZEN trial. Artivion also presented favorable clinical data at a prominent conference and raised its revenue and EBITDA guidance for the year.
Read more →AORTArtivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Artivion, Inc. has treated the first patient in the ARTIZEN pivotal trial, which evaluates the Arcevo LSA Hybrid Stent Graft System for aortic arch pathologies. This multicenter trial aims to support the FDA application for Premarket Approval. The trial will follow 132 participants for up to five years, focusing on safety and efficacy outcomes.
Read more →AORTArtivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Laine Morgan Chief Operating Officer Phone 332-895-3222 Chief Financial Officer investors artivion.com P
Artivion, Inc. reported strong financial results for the third quarter of 2025, achieving revenues of $113.4 million, an 18% increase from the previous year. The company also reported a net income of $6.5 million, in contrast to a loss during the same period last year. Adjusted EBITDA increased significantly to $24.6 million, demonstrating robust operational performance. Additionally, Artivion enrolled the first patient in its ARTIZEN trial for Arcevo, highlighting ongoing clinical advancements. The company has raised its revenue and EBITDA guidance for the full year of 2025.
Read more →AORTArtivion to Participate in the Stifel 2025 Healthcare Conference
Artivion, Inc. will participate in the Stifel 2025 Healthcare Conference on November 12, 2025. The event will feature a fireside chat at 8:00 a.m. ET, accessible via a live webcast on the company's website. Artivion specializes in solutions for aortic disease and markets its products globally.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
Artivion, Inc. has announced that it will release its third quarter 2025 financial results on November 6, 2025, after market close. A teleconference will follow at 4:30 p.m. ET, featuring a Q&A session with CEO Pat Mackin. The event will be accessible via phone and webcast, with replays available shortly after.
Read more →AORTArtivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
Artivion, Inc. presented positive data from its AMDS PERSEVERE and PROTECT trials at the EACTS Annual Meeting. The AMDS PERSEVERE trial showed an 83% resolution rate for visceral malperfusion and 74% for renal malperfusion within 30 days post-implantation. The PROTECT trial validated these findings with real-world data, highlighting the effectiveness of the AMDS hybrid prosthesis in treating acute DeBakey Type I aortic dissections.
Read more →AORTArtivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Artivion, Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. The event will be held at the Sheraton New York Times Square Hotel, with a fireside chat scheduled for 2:35 PM ET. A live webcast will be available on Artivion's website, along with an archived version for 90 days.
Read more →AORTArtivion Reports Second Quarter 2025 Financial Results Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an...
Artivion, Inc. announced strong financial results for the second quarter of 2025, achieving revenues of $113.0 million, a 14% increase on a constant currency basis compared to the same period in 2024. The company reported a net income of $1.3 million, a significant improvement from a net loss in the prior year. Additionally, Artivion received IDE approval for its Arcevo LSA pivotal trial and raised its revenue and EBITDA guidance for the full year 2025, reflecting increased confidence in its growth trajectory. The positive performance was driven by notable gains in key product areas, underscoring the company's strong commercialization efforts.
Read more →AORTArtivion Gilmartin Group LLC Lance A. Berry Brian Johnston Laine Morgan Executive Vice President Phone 332-895-3222 Chief Financial Officer investors artivion.com Phone 770-419-3355 Artivio
Artivion, Inc. reported strong financial results for the second quarter of 2025, achieving revenues of $113.0 million, a 15% increase over the same quarter in 2024. The company also recorded a net income of $1.3 million, marking a turnaround from a loss in the previous year. Strong performance was driven by notable growth in key products, including On-X and stent grafts, which both saw increases of 24%. Additionally, Artivion received FDA approval for an investigational device exemption to begin a pivotal trial for a new treatment for aortic arch pathologies.
Read more →AORTArtivion to Participate in Upcoming Investor Conferences
Artivion, Inc. will participate in two investor conferences in August 2025. The management team is set to present at the Canaccord Genuity 45th Annual Growth Conference and will also engage in investor meetings at the Needham Virtual MedTech & Diagnostics Conference. These events reflect Artivion's ongoing efforts to connect with investors and share insights about its innovations in cardiac and vascular surgery.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025...
Artivion, Inc. announced that it will release its second quarter 2025 financial results on August 7, 2025, after the market closes. A teleconference call is scheduled for the same day at 4:30 p.m. ET, where company executives will discuss the results and answer questions. Artivion focuses on providing innovative medical solutions for cardiac and vascular surgery, specifically targeting aortic disease.
Read more →AORTArtivion to Participate in Upcoming Investor Conferences Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in...
Artivion, Inc. (NYSE: AORT) has announced its participation in two upcoming investor conferences on June 17, 2025. The management team will present at the Truist Securities MedTech Conference and will also engage in meetings at the Citizens Medical Devices and Healthcare Services Forum. The company's focus on aortic diseases highlights its commitment to addressing significant challenges in cardiac and vascular surgery. A webcast of the Truist conference will be available on Artivion's website for those unable to attend.
Read more →AORTArtivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions...
Artivion, Inc. has successfully closed transactions to exchange approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 for over 4.3 million shares of common stock. This transaction effectively eliminates a significant portion of its outstanding debt, thereby improving the company's financial leverage and balance sheet flexibility. The company also made a cash payment for accrued interest as part of the exchange. Following these transactions, a small amount of convertible notes remains outstanding.
Read more →AORTArtivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, ...
Artivion, Inc. has announced agreements to exchange approximately $95 million in principal amount of its 4.250% Convertible Senior Notes due 2025 for shares of its common stock. The number of shares to be issued will be determined based on the stock's trading price over a four-day average starting May 15, 2025. The transactions are expected to provide an opportunity to reduce debt, though they are contingent on customary closing conditions and involve unregistered shares. The expected closing date for these exchanges is on or about May 28, 2025.
Read more →AORTArtivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new...
Artivion, Inc. announced promising 30-day results from the NEXUS TRIOMPHE IDE trial presented at the 105th AATS Annual Meeting. The data indicate significant reductions in major adverse events for patients treated with the NEXUS device, which provides a minimally invasive treatment option for chronic aortic dissection. Dr. Bradley Leshnower highlighted the device's effectiveness compared to FDA performance goals, anticipating further positive outcomes as the trial progresses. The company is optimistic about filing a clinical module for regulatory approval after concluding one year of follow-up with patients.
Read more →AORTArtivion Reports First Quarter 2025 Financial Results First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an...
Artivion, Inc. reported its financial results for the first quarter of 2025, highlighting a revenue increase to $99 million compared to $97.4 million in 2024. The growth was primarily driven by improvements in product sales, especially in stent grafts, On-X valves, and BioGlue. However, preservation services revenue saw a significant decrease due to challenges from a recent cybersecurity incident. The company has revised its revenue guidance upwards for the full year, demonstrating strong confidence in ongoing growth initiatives.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025...
Artivion, Inc. has announced the release date for its first quarter 2025 financial results, which is set for May 5, 2025, after market close. A teleconference and live webcast will follow at 4:30 p.m. ET, featuring a Q&A session with CEO Pat Mackin. Investors can access the results and follow along via the Artivion website, which will also host the earnings press release with comprehensive financial details.
Read more →AORTArtivion Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an...
Artivion, Inc. announced its fourth quarter and full year 2024 financial results, highlighting significant revenue growth and the successful acquisition of a Humanitarian Device Exemption for AMDS from the FDA. The company's fourth-quarter revenues reached $97.3 million, up from $93.7 million in the same quarter last year. While Artivion experienced a net loss of $(16.5) million for the quarter, it remains optimistic about future performance, projecting revenue growth of 10% to 14% for 2025. The company also plans to address challenges posed by a recent cybersecurity incident.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full...
Artivion, Inc. announced the release date for its fourth quarter and full year 2024 financial results, scheduled for February 24, 2025. Following the release, a teleconference call will be held at 4:30 p.m. ET, allowing for discussion of the results and a Q&A session with the company's CEO. This event underscores the company's commitment to engaging with investors and providing updates on its financial performance and strategic initiatives.
Read more →AORTArtivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE...
Artivion, Inc. announced promising results from the AMDS PERSEVERE trial, presented at the 61st Society of Thoracic Surgeons Annual Meeting. The trial data showed sustained benefits of the AMDS device in treating acute DeBakey Type I aortic dissections, with low mortality rates and no new instances of distal anastomotic new entry tears. These findings bolster the company's application for U.S. FDA premarket approval of the AMDS, which they anticipate receiving by late 2025.
Read more →AORTArtivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug...
Artivion, Inc. announced that the FDA has granted a Humanitarian Device Exemption for its AMDS Hybrid Prosthesis, aimed at treating acute DeBakey Type I dissections with malperfusion. This designation allows the device's distribution ahead of future Premarket Approval. Clinical trial results indicate a notable decrease in mortality and adverse events when using AMDS compared to current standard procedures. The company is preparing to expand access to the device while continuing towards obtaining full PMA approval expected in late 2025.
Read more →AORTDocument FOR IMMEDIATE RELEASE Contacts Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Laine Morgan Executive Vice President Phone 332-895-3222 Chief Financial Officer investors artivion.com Phone 770-419-335
Artivion, Inc. announced that the FDA has granted a Humanitarian Device Exemption for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This device, which received Breakthrough Designation, demonstrated a 72% reduction in all-cause mortality and a 54% decrease in major adverse events during clinical trials. The approval allows for commercial distribution in the U.S., with potential annual market opportunities estimated at $150 million. Artivion aims to work with healthcare providers to expand access to this innovative treatment while preparing for a future application for full Premarket Approval.
Read more →AORTArtivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an...
Artivion, Inc. reported strong financial results for the third quarter of 2024, with revenues reaching $95.8 million, a 9% increase compared to the same period in 2023. The company saw significant growth across its product portfolio, particularly in On-X, BioGlue, and stent grafts. Notably, important R&D advancements were achieved, including the approval of BioGlue in China and promising trial data presented at EACTS. While the company experienced a net loss, it is narrowing its revenue guidance upward for the full year 2024, signaling optimism for future financial performance.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024...
Artivion, Inc. has announced the release date for its third quarter 2024 financial results, which will be available on November 7, 2024, after market close. The company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day to discuss these results. This event will include a question and answer session with CEO Pat Mackin, allowing for interaction with stakeholders. Artivion specializes in medical devices related to cardiac and vascular surgeries, particularly focusing on aortic diseases.
Read more →AORTArtivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and...
Artivion, Inc. (NYSE: AORT) presented significant clinical trial data at the 38th EACTS Annual Meeting, highlighting the effectiveness of its products. The AMDS DARTS trial showed durable aortic remodeling with 94% of patients free from unanticipated reoperation over five years. Additionally, the AMDS PERSEVERE trial demonstrated a 90% resolution rate for cerebral malperfusion at 30 days post-implantation. Furthermore, the NEOS study reinforced the safety and effectiveness of the E-vita Open Neo in treating aortic arch pathologies after one year.
Read more →AORTArtivion Reports Second Quarter 2024 Financial Results Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an...
Artivion, Inc. reported strong financial results for the second quarter of 2024, with revenues reaching $98 million, marking a 10% increase compared to the same period last year. Adjusted EBITDA grew by 35%, reflecting the company's operational growth. The leadership has raised revenue and adjusted EBITDA guidance for the full year, indicating positive future expectations. However, the company did report a net loss of $2.1 million, though this represented an improvement from the previous year.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024...
Artivion, Inc. announced the release date for its second quarter 2024 financial results, set for August 8, 2024, after market close. A teleconference and live webcast will follow at 4:30 p.m. ET, hosted by the company's CEO Pat Mackin. This event allows stakeholders to gain insights into the company's financial performance and future outlook, emphasizing its commitment to transparency and engagement.
Read more →AORTDocument FOR IMMEDIATE RELEASE Contacts Artivion, Inc. Lance A. Berry Executive Vice President Chief Financial Officer Phone 770-419-3355 Gilmartin Group LLC Brian Johnston Laine Morgan Phone 332-895-3222 investors artiv
Artivion, Inc. has amended its agreements with Endospan, providing an additional $25 million in debt funding aimed at obtaining FDA approval for the NEXUS Stent Graft System. The upfront payment for acquiring Endospan has been reduced to $135 million, and the previous earnout minimum has been eliminated. With NEXUS being the first approved branched system for aortic arch disease treatment, Artivion sees a considerable market opportunity. The amendments expect to solidify Artivion's leadership in aortic repair, although regulatory and clinical trial risks remain pertinent.
Read more →AORTArtivion Amends Agreements with Endospan Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit...
Artivion, Inc. has amended its financial agreements with Endospan Ltd. regarding the NEXUS Stent Graft System used for treating aortic arch disease. The amendments include an additional $25 million debt funding to facilitate FDA approval processes and reduced purchase option terms. Artivion aims to solidify its leadership in aortic repair as the NEXUS technology demonstrates significant potential in the minimally invasive surgical space. However, potential risks include uncertainties surrounding FDA approval timelines and competitive technologies that may impact market dynamics.
Read more →AORTArtivion Reports First Quarter 2024 Financial Results First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an...
Artivion, Inc. reported strong financial results for the first quarter of 2024, with total revenues reaching $97.4 million, a 17% increase over Q1 2023. The growth was primarily driven by significant contributions from tissue processing and stent grafts, coupled with robust performance in the Latin American market. Additionally, the company is optimistic about future performance, raising its revenue expectations for the full year while showcasing positive clinical results from the On-X aortic valve study. However, the results were impacted by currency revaluation losses.
Read more →AORTArtivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion, Inc. (NYSE: AORT) will virtually participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2023. The event will feature a fireside chat accessible via a webcast on the company's website. Artivion specializes in solutions for aortic diseases, offering a range of products including stent grafts and heart valves. The archived webcast will be available for 90 days following the live event.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full...
Artivion, Inc. announced the release date for its fourth quarter and full year 2023 financial results, scheduled for February 15, 2024. The company will hold a teleconference at 4:30 p.m. ET on the same day to discuss these results, followed by a Q&A session with CEO Pat Mackin. This event will allow stakeholders to receive direct insights into the company’s performance and future outlook. Financial details will be available through their website and during the teleconference.
Read more →AORTArtivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of results...
Artivion, Inc. announced positive results from the AMDS PERSEVERE trial, presented at the Society of Thoracic Surgeons annual meeting. The trial showed a 72% reduction in all-cause mortality and a 52% decrease in primary major adverse events at 30 days post-implantation compared to the standard hemiarch procedure. Notably, there were zero occurrences of distal anastomotic new entry (DANE) in the study participants. The results support the AMDS Hybrid Prosthesis as a significant advancement in treating acute DeBakey Type I aortic dissections, with a promising potential for FDA approval.
Read more →AORTArtivion Obtains $350 Million in Senior Secured Credit Facilities Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of a...
Artivion, Inc. has successfully closed a $350 million senior secured credit facility with Ares Management Credit funds. This financing includes a term loan, a revolving credit facility, and additional delayed draw commitments designed to enhance the company's capital structure. The new credit agreement will help retire existing debt and provides flexibility for future financial strategies. Artivion's leadership believes this move positions the company well for a new phase of growth and shareholder value enhancement.
Read more →AORTArtivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A....
Artivion, Inc. has appointed Lance A. Berry as its new Chief Financial Officer, effective December 4, 2023, replacing retiring CFO D. Ashley Lee. Mr. Berry brings extensive experience from his previous roles in leading MedTech companies, including Wright Medical Group. The company reaffirmed its financial guidance for the year, demonstrating ongoing confidence in its strategic direction. Lee will assist with the transition as an advisor, emphasizing continuity during this leadership change.
Read more →AORTArtivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President, Phone 332-895-3222 Finance investors artivion.com Phone 770-419-3355 Artivion Appoints Lance A
Artivion, Inc. has appointed Lance A. Berry as its new Chief Financial Officer, effective December 4, 2023, succeeding the retiring D. Ashley Lee. Mr. Berry brings a wealth of experience from his previous role at Wright Medical Group and is expected to enhance the company's strategic growth in aortic technology. During this transition, Mr. Lee will remain as an advisor to ensure continuity. The company has reaffirmed its full-year 2023 financial guidance, reflecting confidence in its operations and leadership.
Read more →AORTArtivion Announces Completion of Enrollment in PERSEVERE Trial Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed...
Artivion, Inc. has announced the successful completion of enrollment in its PERSEVERE clinical trial, which aims to evaluate the safety and effectiveness of the AMDS Hybrid Prosthesis for patients suffering from acute DeBakey Type I aortic dissection. The trial will involve 93 participants and is essential for the company's future FDA application for premarket approval. Positive interim results have already been highlighted at a cardiothoracic surgery meeting, indicating potential life-saving benefits associated with the AMDS device. The company anticipates achieving PMA approval in the latter half of 2025.
Read more →AORTArtivion Reports Third Quarter 2023 Financial Results Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third...
Artivion, Inc. reported strong financial results for the third quarter of 2023, with revenues reaching $87.9 million, marking a 14% increase from the same quarter last year. The company's robust performance was highlighted by a 30% increase in aortic stent graft revenue, contributing to the ongoing double-digit growth. Despite a net loss of $9.8 million, an improvement over the previous year, Artivion continues to project positive growth outlooks, raising their full-year revenue guidance. Key milestones include nearing completion of patient enrollment for the PERSEVERE clinical trial, which is critical for future product approvals.
Read more →AORTArtivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President Phone 332-895-3222 Chief Financial Officer investors artivion.com Phone 770-419-3355 Artivion R
Artivion, Inc. announced its financial results for the third quarter of 2023, reporting a revenue increase of 14% year-over-year. The company's net loss decreased compared to the same quarter last year, showing signs of improved operational efficiency. Key product areas like aortic stent grafts showed a significant revenue growth of 30%. Additionally, Artivion is on track to complete its PERSEVERE clinical trial enrollment, aiming for regulatory approval by 2025. The company also raised its revenue guidance for the full year 2023.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023...
Artivion, Inc. has announced its third quarter 2023 financial results will be released on November 2, 2023, after market close. The company will hold a teleconference and live webcast at 4:30 p.m. ET to discuss the results, with a question and answer session led by CEO Pat Mackin. Interested parties can access the teleconference and webcast through the company's website and designated phone lines.
Read more →AORTArtivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the AMDS...
Artivion, Inc. presented positive interim data from the AMDS PERSEVERE trial at the 37th EACTS Annual Meeting, highlighting a significant reduction in all-cause mortality and major adverse events after 30 days of treatment. Among the 52 participants, a striking 79% experienced no target major adverse events. These promising results will support Artivion's upcoming premarket approval submission to the FDA for the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissection.
Read more →AORTArtivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X Aortic...
Artivion, Inc. announced positive interim data from its On-X Aortic Heart Valve Low INR post-market study presented at the 37th EACTS Annual Meeting. The study revealed that the valve remains safe and effective with low-dose warfarin, demonstrating a significantly lower occurrence of thromboembolic events and bleeding compared to historical controls. These results, reflecting an improvement over previous data, reinforce the product’s market positioning as a preferred option for patients requiring valve replacement therapy.
Read more →AORTArtivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the...
Artivion, Inc. announced its participation in the Deutsche Bank 31st Annual Leveraged Finance Conference scheduled for October 3, 2023. The presentation will commence at 10:40 a.m. MST and will be available via a live webcast on the company's website. Artivion specializes in medical devices for cardiac and vascular surgery, particularly for aortic diseases, and offers a range of products including stent grafts and mechanical heart valves. The archived presentation will later be accessible for 90 days.
Read more →AORTArtivion to Present at the Gilmartin Group Emerging Growth Company Showcase Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually ...
Artivion, Inc. (NYSE: AORT) announced it will present virtually at the Gilmartin Group Emerging Growth Company Showcase on September 21, 2023. The presentation aims to highlight the company's advancements in addressing aortic diseases. A live webcast of the presentation will be available on Artivion's website, along with an archived copy for later viewing. Artivion specializes in medical devices for cardiac and vascular surgery, offering products across multiple categories.
Read more →AORTArtivion Reports Second Quarter 2023 Financial Results Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second...
Artivion, Inc. reported strong financial results for the second quarter of 2023, with revenues of $89.3 million, reflecting an 11% increase year-over-year. The company highlighted substantial growth in aortic stent graft and On-X product lines, as well as significant milestones such as FDA approval for PerClot, which garnered a $14.3 million payment. Despite achieving strong revenue growth, Artivion incurred a net loss of $3.4 million due to certain charges. The company has raised its revenue guidance for the full year 2023, anticipating continued robust performance.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023...
Artivion, Inc. announced that it will release its second quarter 2023 financial results on August 3, 2023, after market close. The company will hold a teleconference and live webcast to discuss these results at 4:30 p.m. ET the same day, led by CEO Pat Mackin. Interested parties can participate by dialing in or accessing the webcast through the Artivion website. The earnings press release will also be available for further details on the financial performance.
Read more →AORTArtivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug...
Artivion, Inc. has announced that its PERCLOT Absorbable Hemostatic System received FDA PMA approval, allowing it to control bleeding in various surgical procedures. Following this approval, Artivion will transfer ownership of the PMA to Baxter International, with product shipments commencing upon receiving an $18.75 million milestone payment. Artivion will supply Baxter with PerClot for a minimum of 21 months while they transition manufacturing operations. Both companies expressed optimism about the partnership and its potential to optimize patient care in surgical settings.
Read more →AORTArtivion Reports First Quarter 2023 Financial Results First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first...
Artivion, Inc. reported a revenue of $83.2 million for Q1 2023, reflecting a year-over-year growth of 10% on a constant currency basis. Strong performance was attributed to notable increases in On-X and aortic stent graft sales. The company received an Approvable Letter from the FDA for its PerClot product, signaling potential for future revenue. However, Artivion faced a net loss of $13.5 million in Q1, significantly higher than the previous year. Looking ahead, the company has updated its revenue guidance upwards for 2023.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023...
Artivion, Inc. has announced that it will release its financial results for the first quarter of 2023 on May 4, 2023, after market close. The company will host a teleconference and live webcast at 4:30 p.m. ET on the same day, featuring a Q&A session led by Pat Mackin, the CEO. Additionally, the investors can access detailed financial information on Artivion's website after the earnings release.
Read more →AORTArtivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion, Inc. (NYSE: AORT) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 18, 2023. The event will feature a virtual fireside chat accessible through the company's website. Artivion specializes in solutions for cardiac and vascular diseases, offering products like aortic stents and surgical sealants across more than 100 countries.
Read more →AORT▼ -7.1%on this news
Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion, Inc. will participate virtually in the Oppenheimer 33rd Annual Healthcare Conference scheduled for March 14, 2023. The event will feature a live webcast of a fireside chat accessible through Artivion's website. The company specializes in developing solutions for cardiac and vascular surgeons, particularly in treating aortic diseases and operates globally.
Read more →AORTArtivion Reports Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth...
Artivion, Inc. announced its fourth quarter and full year 2022 financial results, revealing a 9% constant currency revenue growth for the year. Despite achieving strong growth in aortic stent grafts and other segments, the company reported a net loss for 2022 which widened compared to the previous year. The company received a CE Mark for its BioGlue product and expects to secure FDA approval for PerClot. Looking ahead, Artivion anticipates revenue growth between 8% and 12% for 2023 as it continues to expand its workforce and product offerings.
Read more →AORT▲ +7.5%on this news
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full...
Artivion, Inc. (NYSE: AORT) announced it will release its fourth quarter and full year 2022 financial results on February 16, 2023, after market close. The company will host a teleconference and live webcast at 4:30 p.m. ET for discussions about the results, followed by a Q&A session with its CEO, Pat Mackin. The earnings press release will be available on its website in the Investors section, providing additional details and financial data.
Read more →AORTArtivion Reports Third Quarter 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the...
Third Quarter and Recent Business Highlights: ATLANTA , Nov. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2022 . "W
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022...
ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes. On tha
Read more →AORTArtivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President Phone 332-895-3222 Chief Financial Officer investors artivion.com Phone 770-419-3355 Elizabeth
Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President Phone 332-895-3222 Chief Financial Officer investors artivion.com Phone 770-419-3355 Elizabeth Hoff Joins Artivion Board of Directors ATLANTA, GA - (September 29, 2022) - Artivion, In
Read more →AORTElizabeth Hoff Joins Artivion Board of Directors Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A....
ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022 . "We are excited to welcome
Read more →AORT▼ -28.1%on this news
Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President Phone 631-807-1986 Chief Financial Officer investors artivion.com Phone 770-419-3355 Artivion F
Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston Lynn Lewis Executive Vice President Phone 631-807-1986 Chief Financial Officer investors artivion.com Phone 770-419-3355 Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Study Was Evaluating the Use of A
Read more →AORT▼ -28.1%on this news
Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the...
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves The PROACT Xa trial randomized patients having an On-X aortic valve replacement to receive either warfarin or apixaban as their anticoagulant to prevent blood clots. The trial began enroll
Read more →AORTArtivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the...
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 30 th Annual Leveraged Finance Conference on Wednesday, September 21
Read more →AORTArtivion Reports Second Quarter 2022 Financial Results Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second...
ATLANTA , Aug. 4, 2022 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the second quarter ended June 30, 2022. "Duri
Read more →AORTArtivion Initiates Enrollment in PERSEVERE Clinical Trial Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated...
Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission ATLANTA , July 27, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery compan
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022...
ATLANTA , July 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022 financial results will be released on Thursday, August 4, 2022 after the market closes. On that
Read more →AORT▲ +5.1%on this news
Artivion to Participate in the UBS 2022 Global Healthcare Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in...
ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ) , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New
Read more →AORT▼ -7.4%on this news· ran to -22% by day 3
Artivion Reports First Quarter 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the...
Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLANTA , May 5, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardia
Read more →AORT▼ -7.4%on this news· ran to -22% by day 3
xFEFF; FOR IMMEDIATE RELEASE  Contacts: Phone: 770-419-3355 / Lynn Lewis  Artivion D. Ashley Lee Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston /
Phone: 770-419-3355 / Lynn Lewis Artivion D. Ashley Lee Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 investors@a rtivion.com Artivion Reports First Quarter 2022 Financial Results Achie
Read more →AORTArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022...
ATLANTA , April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results will be released on Thursday, May 5, 2022 after the market closes. On that da
Read more →AORTArtivion to Participate in the 21st Annual Needham Virtual Healthcare Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at...
ATLANTA , March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21 st Annual Needham Virtual Healthcare Conference. The Company's virtual fire
Read more →AORTArtivion Publishes Inaugural Corporate Responsibility Report Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate...
ATLANTA , March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Report detailing the company's Environmental, Social, and Governance (ESG) initi
Read more →AORTArtivion to Host Investor & Analyst Day on March 23, 2022 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor...
ATLANTA , March 9, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor & Analyst Day in New York City on Wednesday, March 23, 2022 at 9:00 AM ET . The event will
Read more →AORTArtivion to Participate in the Oppenheimer 32nd Annual Healthcare Conference Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
ATLANTA , March 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 32 nd Annual Healthcare Conference. The Company's virtual
Read more →AORTxFEFF; FOR IMMEDIATE RELEASE  Contacts:   Artivion D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnsto
Artivion Reports Fourth Quarter and Full Year 2021 Financial Results Fourth Quarter and Recent Business Highlights: ATLANTA, GA (February 17, 2022) Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financi
Read more →AORTArtivion Reports Fourth Quarter and Full Year 2021 Financial Results Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth ...
ATLANTA , Feb. 17, 2022 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the fourth quarter and full year ended Decemb
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2021 Financial Results Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full...
ATLANTA , Feb. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the market
Read more →AORTArtivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT...
ATLANTA , Jan. 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society
Read more →AORTxFEFF;  FOR IMMEDIATE RELEASE Contacts:   631-807-1986 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC
631-807-1986 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 investors@cryolife.com CryoLife Announces Corporate Rebranding and Changes N
Read more →AORTxFEFF; FOR IMMEDIATE RELEASE  Contacts: Phone: 770-419-3355 / Lynn Lewis  CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin
Phone: 770-419-3355 / Lynn Lewis CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 investors@cryolife.com CryoLife Reports Third Quarter 202
Read more →AORTxFEFF; N E W S R E L E A S E  FOR IMMEDIATE RELEASE  Contacts:  CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer , and Chief Operating Office r Phone: 770-419-3355 Gilmarti
N E W S R E L E A S E Anthony Semedo Joins CryoLife Board of Directors ATLANTA, GA (September 22, 2021) CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony Tony Semedo to its Board of D
Read more →AORTxFEFF; FOR IMMEDIATE RELEASE  Contacts:   CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnsto
CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter and Recent Business Highlights: ATLANTA, GA (February 11, 2021) CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financia
Read more →AORTCryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986
CryoLife Acquires Ascyrus Medical Conference Call and Webcast Today, September 2, 2020 at 5:00 pm ET Atlanta, GA (September 2, 2020) CryoLife, Inc. ( CryoLife ; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has ac
Read more →AORTCryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 347-620-7010
CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering ATLANTA, GA (June 19, 2020) CryoLife, Inc. (NYSE: CRY) ( CryoLife or the Company ), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million
Read more →AORT Contacts:   CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lyn
CryoLife Provides Business Update in Response to COVID-19 Pandemic ATLANTA, GA (April 1, 2020) CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of
Read more →AORTxFEFF; CRYOLIFE, INC. AND SUBSIDIARIES Financial Highlights (In thousands, except per share data)      (Unaudited) (Unaudited)  Three Months Ended Nine Months Ended 
Phone: 770-419-3355 / Lynn Lewis CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 646-924-1769 investors@cryolife.com CryoLife Reports Third Quarter 201
Read more →AORT Contacts:  Phone: 770-419-3355 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chod
Phone: 770-419-3355 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 646-924-1769 investors@cryolife.com CryoLife Enters Into Distribution Agreement wi
Read more →AORTxFEFF; FOR IMMEDIATE RELEASE  Contacts:   CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone
CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 646-924-1769 investors@cryolife.com Phone: 770-419-3355 CryoLife Reports First Quarter 2019 Financial Results First Quart
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:  CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Offi
CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 646-924-1769 investors@cryolife.com Phone: 770-419-3355 CryoLife Reports Fourth Quarter and Full Year 2018 Financial Resul
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:   CryoLife , Inc. Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chie
CryoLife , Inc. Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 646-924-1769 investors@cryolife.com Phone: 770-419-3355 CryoLife Reports Preliminary Financial Results for Third Qu
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:   CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Opera
CryoLife Gilmartin Group LLC D. Ashley Lee Greg Chodaczek / Lynn Lewis Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 646-924-1769 investors@cryolife.com Phone: 770-419-3355 CryoLife Reports Second Quarter 2018 Results ATLANTA, GA (August
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE Contacts:  Phone: 770-419-3355 CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating O
Phone: 770-419-3355 CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7035 / 7024 tbui@theruthgroup.com / Phone: 770-419-3355 epoalillo@theruthgroup.com Marna Borgstrom Joins Cryo
Read more →AORTxFEFF;  FOR IMMEDIATE RELEASE  Contacts:  CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7035
CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7035 / 7024 tbui@theruthgroup.com Phone: 770-419-3355 epoalillo@theruthgroup.com CryoLife Reports First Quarter 2018 Results Firs
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:  CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-
CryoLife The Ruth Group D. Ashley Lee Tram Bui / Emma Poalillo Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7035 / 7024 tbui@theruthgroup.com Phone: 770-419-3355 epoalillo@theruthgroup.com CryoLife Reports Fourth Quarter and Full Year 201
Read more →AORTCryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 The Ruth Group Zack Kubow 646-536-7020 zkubow@theruthgroup.com Cryo
CryoLife Completes Acquisition of JOTEC Atlanta, GA - (December 1, 2017) - CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JO
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:   CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-
CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536- 7020 zkubow@theruthgroup.com Phone: 770-419-3355 CryoLife Reports Third Quarter 2017 Results Third Quarter and Recent Highlights: ATLANTA, G
Read more →AORTxFEFF; FOR IMMEDIATE RELEASE Contacts:  CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7020 zkubow@theruthgroup.com Phone: 7
CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7020 zkubow@theruthgroup.com Phone: 770-419-3355 CryoLife Announces Definitive Agreement to Acquire JOTEC Provides Access into $2 Billion Glob
Read more →AORTxFEFF;  FOR IMMEDIATE RELEASE Contacts:  Phone: 770-419-3355 CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7020 zku
Phone: 770-419-3355 CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7020 zkubow@theruthgroup.com Phone: 770-419-3355 Jeffrey H. Burbank Joins CryoLife Board of Directors ATLANTA, GA (Octobe
Read more →AORTxFEFF;   FOR IMMEDIATE RELEASE  Contacts:  CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536- 7020 zkub
CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536- 7020 zkubow@theruthgroup.com Phone: 770-419-3355 CryoLife Reports Second Quarter 2017 Financial Results Second Quarter Highlights: ATLANTA,
Read more →AORTxFEFF;  FOR IMMEDIATE RELEASE  Contacts:  CryoLife The Ruth Group D. Ashley Lee Nick Laudico / Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7030
CryoLife The Ruth Group D. Ashley Lee Nick Laudico / Zack Kubow Executive Vice President, Chief Financial Officer and Chief Operating Officer 646-536-7030 / 7020 nlaudico@theruthgroup.com Phone: 770-419-3355 zkubow@theruthgroup.com CryoLife Reports First Quarter 2017 Financial R
Read more →Competitive Position
How AORT ranks across every disease it competes inCompetitive Position is a premium feature
See how AORT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial